Trial Profile
A Phase 2, Randomized, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety, of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Acronyms UC
- Sponsors Amgen; Celgene Corporation
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 21 Jun 2019 This trial has been completed in Bulgarian.
- 13 Jun 2019 This study has been completed in Hungary .